The VCAM-1 increase was significantly lower in the treated groups compared to the BD group: Coversin group FC 14 (8.3–20) (p = 0.008), anti-CD14 group FC 5.3 (3.6–6.9) (p < 0.0001) and the dual treatment group FC 8.9 (5.1–13) (p < 0.0001) (Fig. 5A). The gene discussed is CD14; the disease is Behcet disease.